Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Celgene : Scripps hopes for royalty windfall from potential blockbuster drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/11/2017 | 12:54am CET

Nov. 10--If the new drug ozanimod achieves blockbuster status, it could generate tens of millions of dollars a year in royalties for the Scripps Research Institute -- and provide relief from the ongoing financial challenges facing the nonprofit lab.

Scripps won't say how much it stands to receive from sales of ozanimod, a drug that slows brain atrophy in patients with multiple sclerosis. Scripps discovered the drug, then partnered with Celgene to shepherd the medicine through clinical trials. The biopharmaceutical company expects to begin marketing the drug to MS patients in late 2018.

Celgene (Nasdaq: CELG) also is testing ozanimod as a treatment for ulcerative colitis, which is more common than MS. If ozanimod wins approval as a medicine for the intestinal disorder, sales could reach $4 billion to $6 billion a year.

Scripps says its royalty arrangement with Celgene is confidential. Brian Skorney, an analyst who follows Celgene for Robert W. Baird & Co., said the typical deal pays a drug's inventor "in the low single-digit percentage."

So, if ozanimod's sales reach $4 billion and Scripps gets a 2 percent cut, that would amount to $80 million a year. It would be a welcome windfall for Scripps, which has seen its revenue decline steadily in recent years.

The nonprofit lab's revenue fell to $347.5 million for the year ended Sept. 30, 2016, according to a financial statement, down from $362.5 million the previous year.

It was the fifth consecutive year of declining revenue for San Diego-based Scripps, the scientific juggernaut that's the anchor of Florida's billion-dollar bet on biotech. Scripps in 2016 reported its lowest annual revenue since 2004.

Scripps' net assets dipped to $637 million, down from $647 million in 2015 and the lowest level since 2007.

Dr. Hugh Rosen, a Scripps researcher who's the co-inventor of ozanimod, said the institute's agreement with Celgene calls for royalty payments through 2033 or 2034.

"It could be a significant contributor to the health of the institution," Rosen said.

Patient studies proved that ozanimod is safe and effective, but it's still no sure thing. Skorney said ozanimod faces competition from other MS drugs.

"It's a very crowded space in terms of the number of effective treatments, so we'll see how Celgene ends up pricing it," Skorney said.

Rosen said ozanimod's journey from the lab to the doctor's office underscores the long-term nature of scientific research. In 2002, he started the work that led to ozanimod, and a flurry of tests from 2006 to 2008 ultimately yielded the new drug.

"It will be literally 10 years from discovery to launch for patients, and that's about as fast as you could hope for," Rosen said.

___

(c)2017 The Palm Beach Post (West Palm Beach, Fla.)

Visit The Palm Beach Post (West Palm Beach, Fla.) at www.palmbeachpost.com

Distributed by Tribune Content Agency, LLC.

© Tribune Content Agency, source Regional News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
11/18 SANOFI : Uptake Strategies and Sanofi win capability development prize at PMEA
11/17 CELGENE CORPORATION : and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Ther..
11/15 BEIGENE : Reports Third Quarter 2017 Financial Results
11/15 JOUNCE THERAPEUTICS : Reports Third Quarter 2017 Financial Results
11/11 IMMUNOMEDICS : names ex-Celgene exec its new CEO
11/11 CELGENE : Ozanimod effective against multiple sclerosis, enters New Drug Approva..
11/11 CELGENE : Scripps hopes for royalty windfall from potential blockbuster drug
11/10 CELGENE : Ozanimod Successful in Clinical Trials for Multiple Sclerosis
11/10 ACCELERON PHARMA : Reports Third Quarter 2017 Operational and Financial Results
11/09 CELGENE CORP /DE/ : Entry into a Material Definitive Agreement, Creation of a Di..
More news
News from SeekingAlpha
11/17 Denali Therapeutics Files To Raise $100 Million IPO
11/16 Bluebird's bb2121 nabs accelerated review status in U.S. and Europe
11/16 Watch Out Gilead, Juno's Strategy Might Just Pay Off
11/15 YOUR DAILY PHARMA SCOOP : Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA A..
11/14 Celgene (CELG) Presents at 2017 Stifel Healthcare Conference (Transcript)
Financials ($)
Sales 2017 12 967 M
EBIT 2017 7 267 M
Net income 2017 4 051 M
Debt 2017 4 449 M
Yield 2017 -
P/E ratio 2017 20,38
P/E ratio 2018 15,03
EV / Sales 2017 6,66x
EV / Sales 2018 5,51x
Capitalization 81 960 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 125 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-10.06%81 960
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550